FASLG and cancer: Unlike membrane-bound CD95L (m-CD95L), s-CD95L fails to trigger cell death but instead contributes to aggravating inflammation in chronic inflammatory disorders such as systemic lupus erythematosus (SLE) (O' Reilly et al., 2009; Tauzin et al., 2011) and cancers (Barnhart et al., 2004; Hoogwater et al., 2010; Kleber et al., 2008; Malleter et al., 2013).